← All trials
NCT00717210
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 1999
- Primary completion
- Feb 1, 2005
- Completion date
- Mar 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 318
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Neuro-Oncology Working Group of the German Cancer SocietyLead sponsor
- University of ZurichOverall official - principal investigator
- University of HeidelbergStudy director
- University of LeipzigCollaborator
- German Cancer Research CenterCollaborator
- University of ZurichCollaborator
- University of HeidelbergCollaborator
- University of TuebingenCollaborator
- University of DuesseldorfCollaborator
- University of BonnCollaborator
- Humboldt UniversityCollaborator
- University of Duisburg-EssenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.